HTG Molecular Diagnostics, Inc.
HTGM · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.52 | -2.51 | 1.59 | 1.41 |
| FCF Yield | -0.73% | -0.57% | -0.68% | -0.52% |
| EV / EBITDA | -124.02 | -78.61 | -162.74 | -207.51 |
| Quality | ||||
| ROIC | -63.77% | -33.02% | -39.83% | -29.76% |
| Gross Margin | -11.34% | 16.71% | 46.37% | 31.99% |
| Cash Conversion Ratio | 0.86 | 0.43 | 1.02 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.13% | -9.36% | -14.18% | -17.53% |
| Free Cash Flow Growth | -115.99% | 56.05% | 21.39% | 1.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.20 | 1.67 | -0.68 | -0.60 |
| Interest Coverage | -36.22 | -27.02 | -21.69 | -23.80 |
| Efficiency | ||||
| Inventory Turnover | 1.76 | 2.23 | 0.40 | 0.52 |
| Cash Conversion Cycle | 64.02 | 41.46 | 200.62 | 150.18 |